Furthermore, RES and CIS co-treatment markedly increased ROS production and DNA damage, which may be a consequence of affecting the expression of mitochondrial and cytoplasmic cytochrome c, caspase-9 and activated caspase-3. The gene discussed is CASP3; the disease is in situ carcinoma.